Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian

Breadcrumb

  1. Home
  2. Microbiota 11 - December 2020
  3. Cholesterol metabolism by uncultured human gut bacteria influences host cholesterol level
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Microbiota 11 - December 2020
  3. Cholesterol metabolism by uncultured human gut bacteria influences host cholesterol level
Gastroenterology

Cholesterol metabolism by uncultured human gut bacteria influences host cholesterol level

Cholesterol

Commented articles - Adults' section

By Pr. Harry Sokol
Gastroenterology and Nutrition Department, Saint-Antoine Hospital, Paris, France

 

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

Article2_Bandeau-Microbiota_NL11_FR.jpg

About this article

Author

Image_DT FMT H Sokol Prof Harry Sokol
Created 24 August 2021
Updated 19 August 2024

Comments on the original article of Kenny et al. (Cell Host & Microbe 2020)

The human microbiome possesses extensive metabolic capabilities but our understanding of the mechanisms linking gut microbes to human metabolism remains limited. In this article, the authors focused on the conversion of cholesterol to the poorly absorbed sterol coprostanol by the gut microbiota to develop a framework for the identification of functional enzymes and microbes. By integrating paired metagenomics and metabolomics data from e xisting cohorts with biochemical knowledge and experimentation, the authors predicted and validated a group of microbial cholesterol dehydrogenases that contribute to coprostanol formation. These enzymes are encoded by ismA genes in a group of uncultured microbes, which are prevalent in geographically diverse human cohorts. Individuals harbouring coprostanol-forming microbes have significantly lower faecal cholesterol levels and lower total serum cholesterol with effects comparable to those attributed to variations in lipid homoeostasis genes. Thus, cholesterol metabolism by these microbes may play important roles in reducing intestinal and serum cholesterol concentrations, directly impacting human health. [1]

What do we already know about this subject?

Cholesterol is a key biological molecule that functions as a structural component of all animal cell membranes and is a pre-cursor of steroid hormones, vitamin D, and bile acids. Two main sources of cholesterol are thought to influence concentrations of this metabolite in serum: endogenous cholesterol synthesised in the liver and exogenous cholesterol derived from dietary components of animal origin (Figure 1). The cholesterol synthesised in hepatocytes is transported to the gallbladder and is then secreted into the small intestine along with other bile salts. In the intestine, biliary cholesterol (~1–2 g/day) mixes with dietary cholesterol (~0.2–0.4 g/day in the average American diet), and both sources are eventually transported into enterocytes for packaging into lipoprotein particles and secretion into the plasma. Hypercholesterolaemia is a risk factor for cardiovascular disease (CVD), which is the cause of one-fourth of all deaths in industrialised countries.

Reducing cholesterol transport in the intestine is a clinically validated strategy for lowering serum cholesterol levels. A range of gut microbes metabolise and modify dietary and host-derived molecules in the small intestine. Because both sources of cholesterol pass through this environment, the gut microbiota may influence serum cholesterol levels. Indeed, microbiota transfer from human donors with elevated serum cholesterol levels can impart this hypercholesterolaemia phenotype to mice. [2, 3] Other studies have reported that administering specific bacterial species can have cholesterol-lowering effects. [4] However, the precise mechanisms underlying these observations are currently unknown. The gut microbiota may exert cholesterol-lowering effects by metabolising intestinal cholesterol to coprostanol (Figure 1), which would reduce the amount of cholesterol absorbed from the intestine.

This microbiota-dependent transformation has been known to occur in humans since the early 1900s. Several coprostanol-generating gut bacteria with similar physical and biochemical characteristics have been reported from a variety of different sources including rats, baboons, and humans. However, most of these strains are not currently available and were never sequenced. Early work showed that coprostanol formation by this group of gut bacteria proceeds through an indirect reduction pathway involving the initial oxidation of cholesterol (1) to cholestenone (2), followed by reduction of the D4,5 double bond to form coprostanone (3), and subsequent re-reduction of ketone to generate coprostanol (4) (Figure 1). The bacterial enzymes responsible for this metabolism were never identified. More recently, other reports have implicated additional phylogenetically diverse gut bacteria in coprostanol formation. [5] While efforts to elucidate how gut microbial metabolism of cholesterol affects human serum cholesterol levels span over 100 years, mechanistic support for this connection has remained elusive due to a limited understanding of the gut microbes, genes, and enzymes responsible for coprostanol formation.

Image

Key points

  • Some bacteria found in the human intestinal microbiota possess enzymes belonging to the ismA family capable of breaking down cholesterol.

  • The presence of ismA+ species in gut microbiota is associated with decreased faecal and serum cholesterol in humans.

  • The effect of ismA+ species on serum cholesterol is on par with human genetics.

What are the main insights from this study?

The authors used a multi-disciplinary strategy to discover gut bacterial enzymes. This strategy, based on correlations between metagenomics and metabolomics data from existing human cohorts, identified and characterised an extensive family of cholesterol dehydrogenase enzymes from a clade of uncultured intestinal bacteria implicated in the metabolism of cholesterol to coprostanol. Firstly, the enzyme responsible for the first step in cholesterol transformation, called ismA, was identified in Eubacterium coprostanoligenes, a bacteria already known for this function. Analysis of sequencing data from human cohorts then identified homologous enzymes in a group of uncultured anaerobic bacteria.

The presence of these ismA genes in the microbiome was associated with the presence of coprostanol in stools and lower faecal cholesterol levels. Finally, to demonstrate the potential for these cholesterol- metabolising bacteria to influence human health, the authors showed that presence of ismA genes in human metagenomes is associated with a decrease in total cholesterol concentrations in serum that is on par with the effects observed from variants in human genes involved in lipid homoeostasis

What are the consequences in practice?

Overall, these findings confirm the role of gut-bacterial metabolism in modulating host cholesterol levels in the intestine and also, more importantly, on a systemic level. This work paves the way for the use of the gut microbiota as a predictive biomarker of high cholesterol and establishes the foundations for microbiota-targeted therapeutic interventions.

Conclusion

This study highlights the role of the gut microbiota in breaking down cholesterol with an effect on serum cholesterol levels. Gut microbiota could soon become the target of cholesterol lowering therapies.

Sources

1 Kenny DJ, Plichta DR, Shungin D, et al. Cholesterol metabolism by uncultured human gut bacteria influences host cholesterol level. Cell Host Microbe 2020 ; 28 : 245-57.

2 Le Roy T, Lécuyer E, Chassaing B, et al. The intestinal microbiota regulates host cholesterol homeostasis. BMC Biol 2019 ; 17 : 94.

3 Rothschild D, Weissbrod O, Barkan E, et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 2018 ; 555 : 210-5.

4 Parks DH, Imelfort M, Skennerton CT, et al: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. Genome Res 2015 ; 25 : 1043-55.

5 Gerard P, Lepercq P, Leclerc M, et al. Bacteroides sp. strain D8, the first cholesterol-reducing bacterium isolated from human feces. Appl Environ Microbiol 2007 ; 73 : 5742-9.

Tags
Gastroenterology Microbiome Flora
    Focus
    Microbiota 11 - December 2020
    • Overview
      • The gut microbiota and drug metabolism
      • The gut-lung axis during viral respiratory infections
    • Commented articles
      • Cholesterol metabolism by uncultured human gut bacteria influences host cholesterol level
      • Gut mucosal and faeca l microbiota profiling combined to intestinal immune system in neonate s affected by intestinal ischemic injuries
    • Congress review
      • EJFHOD 2020
    • Press review
      • Vaginal Microbiota #11
      • Skin Microbiota #11
      • Gut Microbiota #11
    Created 24 August 2021
    Updated 19 August 2024

    About this article

    To know more about this topic.

    Main topic

    Cholesterol

    Content type

    Commented article

    Author

    Image_DT FMT H Sokol Prof Harry Sokol
    The gut-lung axis during viral respiratory infections
    Gut mucosal and faeca l microbiota profiling combined to intestinal immune system in neonate s affected by intestinal ischemic injuries
    Focus

    Microbiota 11 - December 2020

    Overview

    The gut microbiota and drug metabolism The gut-lung axis during viral respiratory infections

    Commented articles

    Cholesterol metabolism by uncultured human gut bacteria influences host cholesterol level Gut mucosal and faeca l microbiota profiling combined to intestinal immune system in neonate s affected by intestinal ischemic injuries

    Congress review

    EJFHOD 2020

    Press review

    Vaginal Microbiota #11 Skin Microbiota #11 Gut Microbiota #11
    Gastroenterology
    Photo: Régime méditerranéen « vert » : quels liens entre santé cardiométabolique et microbiote intestinal ?
    10.06.2022

    Green Mediterranean diet: what links between cardiometabolic health and gut microbiota?

    Read the article
    09.01.2025

    3 Keys to a successful consultation by Harry Sokol

    Read the article
    26.05.2025

    Celiac disease: the downside of going gluten-free

    Read the article
    07.02.2025

    Your functional dyspepsia diagnosis check list

    Read the article
    Everything you need to know about the microbiota gut-brain axis
    28.01.2025

    How does the gut microbiota affect the brain?

    Read the article
    Actu PRO : Malnutrition : agir sur le microbiote pour améliorer la croissance, un prototype à l’essai
    08.07.2021

    Malnutrition: acting on the microbiota in order to improve growth, a trial prototype

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Russian

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    11.06.2025

    How menopause impacts microbiota

    Read the article
    04.06.2025

    A handful of bacteria are the signature of chronic pain

    Read the article
    26.05.2025

    Celiac disease: the downside of going gluten-free

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo